Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to...
Zylox-Tonbridge Medical Technology Secures NMPA Nod for Innovative Iliac Vein Stent System
Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...
Eisai’s Uric Acid Excretion Drug Urece Accepted for Review in China
The Center for Drug Evaluation (CDE) in China has indicated on its website that it...
Hansoh Pharmaceutical Gets NMPA Approval for Type 2 Diabetes and Obesity Drug Trial
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that...
Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China
Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry,...
Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease...
LifeShield Medical Launches China HQ and Advanced Heart System Factory in Suzhou
LifeShield Medical, a leading Sino-German multinational medical device company, has announced the official operation of...
Tencent’s WeDoctor Teams Up with Guiyang for Digital Health Community Initiative
The municipal government of Guiyang has entered into a strategic partnership with WeDoctor Holdings Ltd,...
Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment
Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab),...
HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy
China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD)...
Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan
The General Office of the CPC Central Committee and State Council has released the “Implementation...
AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...
Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial
Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...
NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions
The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...
Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a...
Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements
Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered...
Digital Precision Medicine Secures Over $28 Million in Series C Financing
Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of...
NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin
The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...
Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...
AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...